Arrowhead Pharmaceuticals granted entry in FDA Star pilot program for plozasiran
ARWR•Arrowhead Pharmaceuticals said plozasiran for severe hypertriglyceridemia was granted entry into the FDA Star pilot program. The company plans to submit an NDA to the FDA by year-end 2026.
1. FDA pilot entry
Arrowhead Pharmaceuticals said plozasiran for severe hypertriglyceridemia was granted entry into the FDA Star pilot program. The company plans to submit an NDA for plozasiran to the FDA by year-end 2026.
